OrigiMed is Biotechnology in China that focus on clinical application business. Founded in 2016. They cover business area such as developer, researcher, new technology, clinical application, cancer patient, more comprehensive high-throughput method, extensive bioinformatics analysis, clinical annotation, cancer specific molecular marker, genomic feature, immuno-therapy, clinical advancement, precision medicine.
2016
( 8 years old in 2024 )
Clinical Application
-
5th Floor, Building 3
No. 115 Xinjun Ring Road, Minhang District
Shanghai
China
Private
developerresearchernew technologyclinical applicationcancer patientmore comprehensive high-throughput methodextensive bioinformatics analysisclinical annotationcancer specific molecular markergenomic featureimmuno-therapyclinical advancementprecision medicine
* We use standard office opening hours in near OrigiMed's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
OrigiMed is Biotechnology business from China that founded in 2016 (8 years old in 2024), OrigiMed business is focusing on Clinical Application.
OrigiMed headquarter office and corporate office address is located in 5th Floor, Building 3 No. 115 Xinjun Ring Road, Minhang District Shanghai China.
OrigiMed was founded in China.
In 2024, OrigiMed is currently focus on clinical application sector.
Above is snippet of Google Trends for "clinical application" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with OrigiMed, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
